The wearable glucose monitor developer’s nine-figure series B round included M Ventures, Hikma Ventures, Axa Investment Management, Ascencia, Hikm Taisho, Cirrus Logic and EOFlow.

US-based glucose monitoring technology developer Biolinq closed a $100m series B round featuring corporates Axa, Ascencia Diabetes Care, Hikma, Taisho Pharmaceuticals, Cirrus Logic, EOFlow and Merck on Tuesday.

Venture capital firm RiverVest Venture Partners led the round and was also joined by Longevity Vision Fund, T&W Medical, Global Health Investment Corporation, Able Partners, The Broe Group, Senvest, JDRF T1D Fund, Falcon Edge Capital and Aphelion Capital.

Pharmaceutical firms Merck and Hikma and invested through their respective corporate venturing units, M…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn